Breast Cancer Liquid Biopsy Market To See Record Break Revenue $336,659 thousand By 2027

Pune, Maharashtra, India, February 22 2021 (Wiredrelease) Allied Analytics –:Breast cancer liquid biopsy provides a real-time method for treatment of breast cancer. It is used for collection & analysis of a blood sample taken from patients. It analyses the presence of tumor cell-derived biomarkers such as circulating tumor cells, extracellular vesicles, and circulating tumor DNA. A breast cancer liquid biopsy is a simple, noninvasive, and cost-effective diagnostic tool for breast cancer. Breast cancer is known to be the second most common malignancy across the globe, therefore, liquid biopsy is a very significant tool for breast cancer diagnosis and determination.

The global breast cancer liquid biopsy market size was valued at $87.64 thousand in 2019, and is projected to reach $336,659 thousand by 2027, registering a CAGR of 18.3% from 2019 to 2027.

Download Detailed COVID-19 Impact Sample Report at @ https://www.alliedmarketresearch.com/request-for-customization/7983?reqfor=covid

COVID-19 scenario-

1) Due to the global pandemic all over the world, the medical devices manufacturers are majorly focusing on essential medical devices production including ventilators and diagnostics.

2) However, due to the precautionary measures taken by governments in various regions, the supply chain has been hampered. Which may result in shortage of devices in certain locations.

3) Food and Drugs Administration (FDA), on the other hand, shared a COVID-19 guidance with medical device manufacturers to notify the agency about changes that could affect availability of their products.

The major factors that boosts growth of the breast cancer liquid biopsy market include rise in prevalence of breast cancer, surge in propensity for non-invasive procedures, increase in patient awareness toward breast cancer diagnosis and treatment, intensive R&D in the field of breast cancer, and inclination toward personalized medicine. In addition, technological advancements to detect breast cancer at early stage, rise in demand for better minimally invasive therapies for breast cancer treatment, easy accessibility and high adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) among healthcare professionals, and increase in product approvals are also anticipated to drive growth of the market. However, limitations associated with liquid biopsy testing and lack of access and awareness regarding breast cancer liquid biopsy in underdeveloped countries are expected to hinder growth of the market.

Click Here To Access Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/7983

COVID-19 is a large family of viruses that causes illness ranging from common cold to more severe respiratory diseases. This COVID-19 pandemic has affected breast cancer liquid biopsy reagent kits production and import & export of raw material and finished goods, owing to shutdowns in various COVID-19-affected countries. Temporary disruptions of inputs or production might stress some companies, particularly those with inadequate liquidity. Moreover, delayed shipments & production schedules create financial problems for companies with heavy debts. This, in turn, has limited the impact of COVID-19 on the breast cancer liquid biopsy market.

The global breast cancer liquid biopsy market is segmented into product & service, circulating biomarker, application, and region. Based on product & service, the market is categorized into reagent kits, instruments, and services. The reagent kits segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. Key factors such as advent of novel liquid biopsy reagents that execute circulating biomarker analysis and target enrichment; increase in breast cancer liquid biopsy reagent kits approvals; and increase in funding for breast cancer liquid biopsy R&D are anticipated to drive the growth of the market. In addition, surge in demand for reagent kits, rise in number of breast cancer liquid biopsy test procedures, and increase in prevalence of breast cancer across the globe are other factors that contribute toward growth of the market.

On the basis of application, the market is classified into diagnostics, prognostics, and risk assessment. The diagnostics segment accounted for maximum market revenue in 2019, and is anticipated to maintain its dominant position during the forecast period, owing to rise in number of patients suffering from breast cancer, rise in trend of developing personalized therapeutics, technological advancements in liquid biopsy systems, and increase in patient awareness toward safe and non-invasive liquid biopsy testing procedures

North America accounted for the largest share of the global breast cancer liquid biopsy market in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to increase in prevalence of breast cancer and higher number of R&D activities to develop novel breast cancer liquid biopsy reagent kits. Moreover, large number of target population with higher health awareness, availability of trained medical professionals, and rise in investments by leading market players and hospitals are other factors that fuel growth of the breast cancer liquid biopsy market. 

Asia-Pacific is expected to experience highest growth rate during the forecast period, majorly owing to growth in prevalence of breast cancer and surge in patient awareness toward the use of breast cancer liquid biopsy technique.

To know more about the report, visit the website at @ https://www.alliedmarketresearch.com/breast-cancer-liquid-biopsy-market-A07618

The Major Key Players Are:

Biocept, Inc., F. Hoffmann-La Roche Ltd. (Foundation Medicine, Inc.), Fluxion Biosciences, Inc., Menarini Group (Menarini Silicon Biosystems, Inc.), Myriad Genetics, Inc., NeoGenomics Laboratories, Inc., Qiagen N.V., Sysmex Corporation, and Thermo Fisher Scientific Inc.

Key Findings Of The Study 

•    By product & service, the reagent kits segment held largest breast cancer liquid biopsy market share in 2019, and is expected to remain dominant throughout the forecast period.
•    On the basis of circulating biomarker, the circulating tumor cell segment held largest market share in 2019, and is expected to remain dominant throughout the forecast period. 
•    According to application, the diagnostics segment exhibits fastest growth, and is expected to grow at a CAGR of 19.5% from 2019 to 2027.
•    Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 20.0% during the forecast period.

Similar Reports:

Gastrointestinal Therapeutics and Diagnostics Market: Global Opportunity Analysis and Industry Forecast, 2020-2027

Vaccine Adjuvants Market: Global Opportunity Analysis and Industry Forecast, 2020-2027

Virus Filtration Market: Global Opportunity Analysis and Industry Forecast, 2020-2027

Digital Medicine Market: Global Opportunity Analysis and Industry Forecast, 2020-2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.